The atopic dermatitis market has seen considerable growth due to a variety of factors.
• The market size for atopic dermatitis has seen significant expansion in the previous years. It is anticipated to surge from $8.61 billion in 2024 to a whopping $9.96 billion in 2025, marking a Compound Annual Growth Rate (CAGR) of 15.7%. Factors such as increased medical knowledge and awareness, increasing incidence and prevalence rates, patient advocacy and support, the development of treatment approaches, and research and development efforts have fueled the growth during the historical span.
The Atopic Dermatitis market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of atopic dermatitis is anticipated to experience substantial growth in the coming few years, escalating to $17.45 billion throughout 2029 at a compound annual growth rate (CAGR) of 15.0%.
This growth during the prediction period can be credited to advancements in biologic therapies, immunomodulators, and small molecule drugs, treatments specifically designed for pediatrics, gene therapy, and precision medicine, and integration of digital health. Some of the key trends during this projected period encompass advancements in topical technology, a focus on pediatric ad care, the management of environmental factors and allergens, and tools for precision diagnosis.
The surge in atopic dermatitis cases worldwide is anticipated to boost the expansion of the related market. Atopic dermatitis, also known as eczema, is a condition that results in skin dryness and itching. The escalating incidence of this disease highlights the necessity for its diagnosis and effective treatment. For example, Oxford Academic, a UK-based publisher, has revealed high rates of global occurrence of atopic dermatitis (AD). It impacts around 2.6% of the global population, which equates to approximately 204 million individuals in 2024. This statistic includes around 101 million adults and 103 million children. Consequently, the rising incidence of atopic dermatitis is fueling the growth of the market addressing this disease.
The atopic dermatitis market covered in this report is segmented –
1) By Drug Class: Corticosteroids, Emollients Or Moisturizers, IL-4 And PDE4 Inhibitors, Calcineurin Inhibitors, Antibiotics, Other Drug Classes
2) By Mode of Administration: Topical, Injectable, Oral
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Corticosteroids: Topical Corticosteroids, Systemic Corticosteroids
2) By Emollients Or Moisturizers: Creams and Lotions, Ointments and Balms, Barrier Repair Creams
3) By IL-4 And PDE4 Inhibitors: Dupilumab (IL-4 Inhibitor), Apremilast (PDE4 Inhibitor)
4) By Calcineurin Inhibitors: Tacrolimus Ointment, Pimecrolimus Cream
5) By Antibiotics: Topical Antibiotics, Systemic Antibiotics
6) By Other Drug Classes: Antihistamines, Biologics, JAK Inhibitors
A leading trend catching traction in the atopic dermatitis market is the introduction of innovative product solutions by key market players to consolidate their market presence. For example, in June 2022, Regeneron Pharmaceuticals Inc., a biotechnology company based in the US, obtained FDA clearance for Dupixent (dupilumab). This drug is designed for treating moderate to severe atopic dermatitis in children aged between 6 months and 5 years. Dupixent can be used in conjunction with or independently from topical corticosteroids. It works by blocking the signals of two significant sources of Type 2 inflammation (IL-4 and IL-13), which are integral to the progression of conditions like eosinophilic esophagitis, prurigo nodularis, chronic rhinosinusitis with nasal polyposis, and asthma.
Major companies operating in the atopic dermatitis market include:
• Sanofi SA
• Meda AB
• Regeneron Pharmaceuticals Inc.
• Novartis International AG
• Pfizer Inc.
• AbbVie Inc.
• Astellas Pharma Inc.
• Arcutis Biotherapeutics Inc.
• Asana Biosciences LLC
• Dermavant Sciences Inc.
• Eli Lilly and Company
• Galderma SA
• Incyte Corporation
• Bayer AG
• Bausch Health Companies Inc.
• Boehringer Ingelheim International GmbH
• GlaxoSmithKline PLC
• F Hoffmann-La Roche AG
• LEO Pharma A/S
• Teva Pharmaceutical Industries Ltd.
• Mylan MV
• Allergan PLC
• Encore Dermatology Inc.
• Menlo Therapeutics Inc.
• Johnson & Johnson
• Merck & Co Inc.
• Roche Holding AG
• Valeant Pharmaceuticals International Inc.
• Amgen Inc.
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Eisai Co. Ltd.
• Gilead Sciences Inc.
• Ipsen Biopharmaceuticals Inc.
• Kyowa Kirin Co. Ltd.
• Mallinckrodt Pharmaceuticals Limited
North America was the largest region in the atopic dermatitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atopic dermatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.